Evidence map›Paper›PMID 39631832›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Progress in the Study of Mechanisms Clinically Relevant to Insulin Resistance 
and Lung Cancer].

Xiaoyu Chen, Peng Chen

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiaoyu ChenDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for
Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Peng ChenDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for
Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At present, the incidence and mortality rates of lung cancer rank top among malignant tumors. The early diagnosis, treatment and drug resistance of lung cancer still remain as problems in the management of lung cancer. Researchers are dedicated to identifying reliable biomarkers as predictive indicators or effective therapeutic targets for lung cancer. Insulin resistance (IR), a disorder characterized by reduced biological activity of insulin, leads to increased insulin secretion. In recent years, more and more studies have revealed the association between IR and the occurrence and development of cancer, with the insulin/insulin-like growth factor signaling pathway possibly playing a crucial role. In this article, we will focus on the relationship between IR and lung cancer, explore the impact and mechanism of IR on the development, progression and drug resistance of lung cancer. It may guide the development of new predictive tools and therapeutic strategies, and provide new ideas for research dedicated to reducing the incidence and mortality of lung cancer.
.

Indexed as

Insulin ResistanceLung NeoplasmsAnimalsDrug Resistance, NeoplasmHumansInsulinSignal TransductionInsulinDrug resistanceInsulin-like growth factor 1 receptorInsulin resistanceLung neoplasms

Identifiers

PMID39631832
PMCPMC11629090

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.